ReSViNET
  • Home
  • News
  • Conferences
    • 5th Meeting 2019
    • 4th Meeting 2017
    • 3rd Meeting 2017
    • 2nd Expert Meeting
    • 1st Expert Meeting
  • parents
  • professionals
  • about
    • The foundation
    • Global network
    • Mission Statement
    • Board members
    • Partners
  • patient network
  • Publications
  • contact us

Click here to edit.

Early stage Respiratory Syncytial Virus (RSV) Vaccine Trial Begins

9/23/2018

0 Comments

 
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched a clinical trial of an investigational vaccine designed to protect against respiratory syncytial virus (RSV). The Phase 1 study will enroll a small group of healthy adult volunteers to examine the safety of an experimental intranasal vaccine and its ability to induce an immune response. The study is being conducted at the Cincinnati Children’s Hospital Medical Center, one of the NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs). 

Read more here.
Picture
0 Comments



Leave a Reply.

    Archives

    February 2019
    January 2019
    October 2018
    September 2018
    May 2018
    March 2018
    January 2018
    January 2017
    December 2016
    June 2016
    March 2016
    February 2016
    October 2015
    September 2015
    May 2015
    April 2015
    February 2015
    January 2015
    October 2014
    September 2014
    July 2014
    January 2014

    RSS Feed

Note: All information on ReSViNET is for educational purposes only. For specific medical advice, diagnoses, and treatment, consult your doctor.

2018 ReSViNET. All rights reserved.
about us
disclosure
contact
  • Home
  • News
  • Conferences
    • 5th Meeting 2019
    • 4th Meeting 2017
    • 3rd Meeting 2017
    • 2nd Expert Meeting
    • 1st Expert Meeting
  • parents
  • professionals
  • about
    • The foundation
    • Global network
    • Mission Statement
    • Board members
    • Partners
  • patient network
  • Publications
  • contact us